Sophie Jabban

Sophie Jabban

Auto-generated profile, based on publicly available information

Sophie Jabban

New York University Grossman School of Medicine , New York, NY 10010

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2026 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
KMKeizra Mecklai
Keizra Mecklai
NMNaaman Mehta
Naaman Mehta
COCheongeun Oh
Cheongeun Oh
SJSophie Jabban
Sophie Jabban
ABAmy Bleasdale
Amy Bleasdale
MLMichelle Lightfoot
Michelle Lightfoot

12 November 2026 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
SJSophie Jabban
Sophie Jabban
CTCarli Tucci
Carli Tucci
APAkshay Pulavarty
Akshay Pulavarty
NLNayoung Lee
Nayoung Lee
MSMary Stevenson
Mary Stevenson
MCMaressa C. Criscito
Maressa C. Criscito

2 October 2026 in Otology & Neurotology
Verified
Journal Article
Closed access
SJSophie Jabban
Sophie Jabban
SFSpencer Frome
Spencer Frome
KAKara Anstett
Kara Anstett
MHMaya Hatley
Maya Hatley
KYKaleb Yohay
Kaleb Yohay
DSDevorah Segal
Devorah Segal
Objective: Identify response rates of vestibular schwannomas in NF2-related Schwanomatosis to treatment with losartan alone or combined with other treatments. Study design: Single-institution retrospective case series. Setting: Tertiary referral center. Patients: Twenty patients with NF2-related Schwannomatosis. Intervention(s): Losartan alone, Losartan plus other therapy (bevacizumab, brigatinib, axitinib). Main outcome measure(s): Volumetric progression, defined as a change in VS size >20%, in accordance with the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) criteria. Audiometric progression is defined as a change in hearing measures, either a 10 dB or greater increase in PTA or a 10% or greater decrease in WRS. Results: This study included 20 patients, with 33 VSs, treated at our institution from 2014 to 2023. Losartan treatment duration ranged from 8.09 to 153.04 months (mean: 53.8, SD: 37.32). Twelve VSs were concurrently managed with antineoplastic therapy. Among 21 VSs treated with losartan alone, volumetric regression, progression, and stability were seen in 23.8%, 47.6%, and 28.6% of tumors, respectively. Among 5 VSs treated with combination losartan and bevacizumab, 40% of tumors regressed, 20% progressed, and 40% remained stable during the combination period. One tumor that progressed during bevacizumab monotherapy treatment achieved volumetric stability following combination therapy. Volumetric growth rates during bevacizumab alone did not significantly differ from growth rates following combination therapy. Conclusions: This case series describes response rates among NF2 -SWN patients treated with losartan. The potential role of losartan in modulating tumor size, either alone or in combination with bevacizumab, should be further studied through well-controlled studies. The study is limited by a small sample size.

23 July 2026 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SJSophie Jabban
Sophie Jabban
RARobert Adler
Robert Adler
APAkshay Pulavarty
Akshay Pulavarty
MCMaressa C. Criscito
Maressa C. Criscito
MPMiriam Keltz Pomeranz
Miriam Keltz Pomeranz

17 July 2026 in Head & Neck
Verified
Journal Article
Closed access
PDF file
AKAllen Khudaverdyan
Allen Khudaverdyan
SJSophie Jabban
Sophie Jabban
EMEmmanuel Garcia Morales
Emmanuel Garcia Morales
LMLindsey Moses
Lindsey Moses
AFAshley Feng
Ashley Feng
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri